| http://www.w3.org/ns/prov#value | - The asthma drug is based on dsco approval of surfaxin, Read the companies old reprots: We are conducting research and preclinical development with our KL4 surfactant potentially to address Acute Lung Injury (ALI), and, potentially in the future, other diseases associated with inflammation of the lung, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD).
|
